Antibody-Drug Conjugates: Cancer Therapies to Watch
There are up to 80 ADCs in clinical development with close to 600 ongoing trials.
Features
FEATURES
Functional Status May Predict Outcomes in Hospitalized Patients With Advanced Cancer
The association between functional impairment and symptom burden was shown to be predictive of outcomes for older patients with advanced cancer.
Explaining Treatment Risks to Patients
Physicians should frame treatment options by their “harms and benefits,” not by their “risks and benefits.”
Treating Strategies for Patients With Relapsed/Refractory Acute Myeloid Leukemia
Although numerous clinical studies have aimed to treat AML, most results have been disappointing, according to authors of a publication in Blood.
Treatment, Remaining Needs Pertaining to Acute Myeloid Leukemia
The current state of AML treatment and remaining needs are discussed in an interview with Courtney D. DiNardo, MD, MSCE and Ghayas C. Issa, MD.
Direct-to-Drug Screening Tool Allows for Precision Medicine in Multiple Myeloma
An assay from Mayo Clinic researchers screens multiple myeloma drugs to see how cells with different biomarkers and pretreatment histories react.
New ASCO Clinical Guidelines on Management of Cancer Cachexia
The American Society of Clinical Oncology published new clinical guidelines on the management of cachexia in adults with advanced cancer.
von Willebrand Disease: Recent Developments in Diagnosis, Treatments
New developments in lab assays have allowed for more specialized assessments of VWD activity, leading to better diagnoses and various treatment options.
When Is Splenectomy Appropriate in Hereditary Hemolytic Anemia?
Investigators discuss surgical approaches and outcomes of total and partial splenectomy for the treatment of hereditary hemolytic anemia in children.
EULAR Recommendations for the Management of Rheumatic Immune-Related Adverse Events Due to Cancer Immunotherapy
A EULAR task force developed recommendations for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy.
Navigating COVID-19: Self-Care Strategies for Oncology Professionals
A review of techniques oncology nurses can use to help themselves cope with their feelings as they navigate through the effects of the COVID-19 pandemic on their practice, their patients, and themselves.
Financial Burden of Childhood Cancer Treatment on Parents
Families affected by the emotional burden of childhood cancer often face significant financial difficulty due treatment expenses and time away from work.
Social Workers Are Underutilized in Oncologic Pain Management
Expertise in the use of nonpharmacologic pain management techniques and therapies allow masters-prepared social workers to be an integral member of a multidisciplinary cancer care team.
ASH 2020 Clinical Guidelines: Sickle Cell Disease and Cerebrovascular Disease
ASH published new clinical guidelines on the prevention, diagnosis, and treatment of CNS complications for children and adults with sickle cell disease.
Clotting and COVID: New Guidelines in the Works to Treat Coagulopathies in Patients With COVID-19
Growing concerns about thromboembolic comorbidities in patients with COVID-19 is leading ASH to create clinical practice guidelines to treat this patient population.
Radiation Therapy for Hematologic Cancers During the COVID-19 Pandemic
ILROG has issued guidelines on alternative radiation treatment methods to combat limited treatment resources for cancer patients during the COVID-19 pandemic.
Tocilizumab Shows Benefit in a Patient With COVID-19 and Multiple Myeloma
IL-6 blockade may have helped a patient with multiple myeloma recover from COVID-19, but larger studies are needed to prove efficacy.
Genetic Mosaicism and Transmission of Hemophilia
Approximately 30% of patients with hemophilia are considered sporadic cases, causing a challenge when determining carrier status and disease transmission risk to offspring.
Seven Things to Consider When Transitioning to Telemedicine During COVID-19
The use of telemedicine has been surging since the onset of COVID-19, with millions of Americans now using this medium for connecting with their clinicians.
Expert Consensus Guidelines for Remission Maintenance With Rituximab in ANCA-Associated Vasculitis
An expert panel of clinicians developed guidelines for the use of rituximab in the maintenance of remission for adult ANCA-associated vasculitis.
Hydroxychloroquine for SARS-CoV-2 Infection: How Did We Get Here?
Hydroxychloroquine is a less-toxic metabolite of the antimalarial drug chloroquine and is used as an immunomodulator for the treatment of autoimmune diseases.
Managing Pegasparaginase Toxicities in Adults With Acute Lymphoblastic Leukemia
Survival outcomes are relatively high for children with ALL but genetics, insufficient chemotherapy treatment, and the risk of relapse may factor into the reduced survival outcomes in adult patients.
Communicating With the Transgender Patient With Cancer
Transgender patients present unique communication as well as clinical challenges for oncology clinicians.
Reviewing the Latest Treatment Strategies in Patients with Transplant-Eligible Multiple Myeloma
An expanding range of treatment options in the past decade has led to greater long-term survival in patients with multiple myeloma.
COVID-19 Pandemic Delaying Treatments of Hematologic Cancers
Some US medical centers have canceled treatments and all centers have altered their policies and procedures out of precaution related to the COVID-19 pandemic.
Chronic Lymphocytic Leukemia Treatment Decision Making With Venetoclax-Based Therapy
A review of case studies that outline treatment decisions based on patient and disease characteristics.
Case Study: Understanding May-Hegglin Anomaly
During a routine physical examination, a clinician suspects May-Hegglin anomaly because of the patient’s low platelet count and hearing loss.
Increasing the Representation of Older Adults in Blood Cancer Trials
Older adults are often underrepresented in trials either because of comorbidities that cause them to be excluded, or through unconscious bias on the part of study teams.
Combating COVID-19: Best Practices That Clinicians Need to Know
How should clinicians combat coronavirus disease (COVID-19) in their practice settings?
Do Patients With Cancer Need Disease-Specific Precautions to Prevent COVID-19 Infection?
Although some patients with cancer are at higher risk of developing severe disease should they become infected, these experts suggest the precautions being given to the general population are sufficient — at least for now.
Toxicity Management in the Era of Novel Therapies for Hematologic Malignancies
Researchers provided an overview of toxicities associated with the use of novel agents to treat hematologic malignancies, as well as potential management strategies.
New ASH Clinical Guidelines on Transfusion Support for Sickle Cell Disease
A panel of researchers developed evidence-based guidelines to support clinical decision making regarding transfusion support for patients with sickle cell disease.
Managing Complications Associated With Increased Longevity in Beta Thalassemia
As the life expectancy for patients with beta thalassemia continues to increase, more and more patients are experiencing age-related complications.
Peripheral Neuropathy Complicates Treatment of Hematologic Malignancies
Treatment regimens including immunomodulatory agents or proteasome inhibitors could lead to development of peripheral neuropathy.
Current and Prospective Treatment Options for Waldenström Macroglobulinemia
Researchers discussed diagnostic considerations, indications for therapy, and treatment options for patients with Waldenström macroglobulinemia.
Personalizing Intensive Therapy for Older Patients With Hematologic Cancers
Several factors need to be considered when choosing optimal therapy for older patients with hematologic malignancies, particularly when it comes to managing toxicity.
Considering Personalized Neoantigen Vaccine Approaches for Multiple Myeloma
Neoantigens may have the ability to provoke the immune system into recognizing and killing cancer cells in patients with multiple myeloma.
CAR-T Therapy: Supporting Evidence and Value Considerations
Although CAR-T therapies have shown favorable response rates, they can be incredibly costly and may not be priced in alignment with their benefits.
Diagnosis and Management of Thrombocytopenia in Pregnancy
Researchers reviewed the diagnosis and management of several pregnancy-specific causes of thrombocytopenia.
Some Targeted Therapies May Miss the Mark
Ten different drugs continued to kill cancer cells even when their target proteins were removed.
Expert Q&A: The Current State of Gene Therapy for Hemophilia
Although gene therapy shows promise in curing hemophilia, questions about its efficacy, optimal administration, and outcomes remain.
Immunoglobulin Replacement May Benefit Some Patients Receiving CAR-T Therapy
CAR-T therapy can sometimes lead to immune system dysfunction, subsequent hypogammaglobulinemia, and the need for antibody replacement therapy.
Treatment Strategies for Lymphoma in Patients With HIV
Cancer, particularly non-Hodgkin lymphoma, remains a leading cause of death in patients with HIV who are being treated with antiretroviral therapy.
British Society of Hematology Guideline Update for Point-of-Care Testing in Hematology
Researchers reviewed currently available point-of-care technology and provided recommendations for standardizing use of this technology.
Updated Guidance on Managing Bleeding and Surgery on Antiplatelet Therapy
Antiplatelet therapy is used to manage cardiovascular events but can lead to increased risk for bleeding events both mild and severe.
Can CAR-T Be Optimized for Multiple Myeloma?
To tweak CAR-T therapies for myeloma, researchers are trying to repurpose a failed Alzheimer’s drug and are extracting patients’ T cells sooner.
Resting vs Activated Platelets: Why Knowing the Difference Makes Financial Sense
Transfusing activated platelets can increase the number of transfusions required and thus lead to additional costs compared with transfusing resting platelets.
Treating Venous Thromboembolism in Patients With Cancer: 2019 Clinical Practice Guidelines
This 2019 guideline update includes a review of new data on anticoagulant use and risk stratification in venous thromboembolism.
Expert Q&A: Addressing the Survivorship Gap in Pediatric Hodgkin Lymphoma
Refining primary treatment and emphasizing secondary treatment can help mitigate the survivorship gap faced by many pediatric survivors of HL.
VTE Risk and Incidence in Hospitalized Patients With Blood Cancers
A new study aims to address the conundrum of coagulation risk in patients hospitalized for hematologic malignancies.
-
Loading...
-
Loading...
Want to read more?
Please login or register first to view this content.
